Researcher Profiles

Return to member profile

Stephen K. Burley, MD, DPhil

Selected Publications

  1. D.B. Nikolov, S.-H. Hu, J.P. Lin, A. Gasch, A. Hoffmann, M. Horikoshi, N.-H. Chua, R.G. Roeder, and S. K. Burley (1992) Crystal structure of TFIID TATA-box binding protein. Nature 360, 40-46.
  2. A.R. Ferre-D'Amare, G.C. Prendergast, E.B. Ziff, and S.K. Burley (1993) Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature 363, 38-45.
  3. K.L. Clark, E.D. Halay, E. Lai, and S.K. Burley (1993) Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364, 412-420.
  4. J.L. Kim, D.B. Nikolov, and S.K. Burley (1993) Co-crystal structure of TBP recognizing the minor groove of a TATA element. Nature 365, 520-527.
  5. A.R. Ferre-D'Amare, P. Pognonec, R.G. Roeder, and S.K. Burley (1994) Structure and function of the b/HLH/Z domain of USF. EMBO Journal 13, 180-189.
  6. L.E. Canne, A.R. Ferré-D'Amaré, S.K. Burley, and S.B.H. Kent (1995) Total chemical synthesis of a unique transcription factor-related protein: cMyc-Max. Journal of the American Chemical Society 117, 2998-3007.
  7. D.B. Nikolov, H. Chen, E.D. Halay, A. Usheva, K. Hisatake, D.K. Lee, R.G. Roeder, and S. K. Burley (1995) Crystal structure of a TFIIB-TBP-TATA element ternary complex. Nature 377, 119-128.
  8. X. Xie, S.L. Cohen, U. Mirza, B.T. Chait, A. Hoffmann, R.G. Roeder, Y. Nakatani, and S. K. Burley (1996) Structural similarity between TAFs and the heterotetrameric core of the histone octamer. Nature 380, 316-322.
  9. J. Marcotrigiano, A.-C. Gingras, N. Sonenberg, and S.K. Burley (1997) Co-crystal structure of the messenger RNA 5’ Cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89, 951-961.
  10. J. Marcotrigiano, A.-C. Gingras, N. Sonenberg, and S.K. Burley (1999) Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Molecular Cell 3, 707-716.
  11. G. Patikoglou, J.L. Kim, L. Sun, S.-H. Yang, T. Kodadek, and S.K. Burley (1999) TATA element recognition by the TATA box-binding protein has been conserved throughout evolution. Genes and Development 13, 3217-3230.
  12. K.S. Gajiwala, H. Chen, F. Cornille, B.P. Roques, W. Reith, B. Mach, and S.K. Burley (2000) Structure of a winged-helix protein reveals a new mode of DNA binding. Nature 403, 916-921.
  13. K. Kamada, F. Shu, H. Chen, S. Malik, M. Meisterernst, R.G. Roeder, and S.K. Burley (2001) Crystal structure of negative cofactor 2 recognizing the TBP-DNA transcription complex. Cell 106, 71-81.
  14. S. Atwell, J.M. Adams, J. Badger, M.D. Buchanan, I.K. Feil, K.J. Froening, X. Gao, J. Hendle, K. Keegan, B.C. Leon, H.J. Muller-Dieckmann, V.L. Nienaber, B.W. Noland, K. Post, K.R. Rajashankar, A. Ramos, M. Russell, S.K. Burley, and S.G. Buchanan (2004) A novel mode of Gleevec (STI-571, Imatinib) binding is revealed by the structure of spleen tyrosine kinase (Syk). Journal of Biological Chemistry 279, 55827-55832.
  15. S.K. Burley (2005) Fragment-Based Lead Discovery and Structure-Guided Design to Discovery of Small Molecule Inhibitors of BCR-ABL Tyrosine Kinase Active Against the T315I Imatinib-Resistant Mutant. Blood 106. Abstract No. 698.
  16. J. Blaney, V. Nienaber, and S.K. Burley (2006) Fragment-based Lead Discovery and Optimization Using X-ray Crystallography, Computational Chemistry, and High-Throughput Organic Synthesis. In Fragment-based Approaches in Drug Discovery, edited by W. Jahnke and D.A. Erlanson (WILEY-VCH Verlag GmbH and Co., KGaA, Weinheim) pp. 215-248.
  17. T. O'Hare, C.A. Eide, J.W. Tyner, A.S. Corbin, M.J. Wong, S. Buchanan, K. Holme, K.A. Jessen, C. Tang, H.A. Lewis, R.D. Romero, S.K. Burley, and M.W. Deininger (2008) SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proceedings of the National Academy of Sciences USA 105, 5507-5512.
  18. S.G. Buchanan, J. Hendle, P.S. Lee, C.R. Smith, P.Y. Bounaud, K.A. Jessen, C.M. Tang, N.H. Huser, J.D. Felce, K.J. Froning, M.C. Peterman, B.E. Aubol, S.F. Gessert, J.M. Sauder, K.D. Schwinn, M. Russell, I.A. Rooney, J. Adams, B.C. Leon, T.H. Do, J.M. Blaney, P.A. Sprengeler, D.A. Thompson, L. Smyth, L.A. Pelletier, S. Atwell, K. Holme, S.R. Wasserman, S. Emtage, S.K. Burley, and S.H. Reich (2009) SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Molecular Cancer Therapeutics 8, 3181-3190.
  19. S.K. Burley, G. Hirst, P. Sprengeler, and S. Reich (2010) Fragment-Based Structure-Guided Drug Discovery: Strategy, Process, and Lessons from Human Protein Kinases. In Drug Design Structure- and Ligand-Based Approaches, edited by K.M. Merz, Jr., D. Ringe, and C.H. Reynolds (Cambridge University Press, Cambridge).
  20. S. Knapp, P. Arruda, J. Blagg, S. Burley, D.H. Drewry, A. Edwards, D. Fabbro, P. Gillespie, N.S. Gray, B. Kuster, K.E. Lackey, P. Mazzafera, N.C.O. Tomkinson, T.M. Willson, P. Workman and W.J. Zuercher (2013) A public-private partnership to unlock the untargeted kinome. Nature Chemical Biology 9, 3–6.
  21. T.J. Wu, X. Wang, Y. Zhang, L. Meng, J.E. Kerrigan, S.K. Burley, and X.F. Zheng (2015) Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase. Cell Reports 11, 446-459.